Hi,
moomoo ID:NaN
Log Out
English
Back
Log in to access Online Inquiry

FY2022 EPS Estimates for Avivagen Inc. Decreased by Zacks Small Cap (OTCMKTS:VIVXF)

Defense World ·  {{timeTz}}

Avivagen Inc. (OTCMKTS:VIVXF – Get Rating) – Investment analysts at Zacks Small Cap reduced their FY2022 EPS estimates for shares of Avivagen in a note issued to investors on Wednesday, August 31st. Zacks Small Cap analyst D. Bautz now anticipates that the company will earn ($0.08) per share for the year, down from their prior estimate of ($0.07). The consensus estimate for Avivagen's current full-year earnings is ($0.07) per share.

Get Avivagen alerts:

Avivagen (OTCMKTS:VIVXF – Get Rating) last announced its quarterly earnings results on Wednesday, June 15th. The company reported ($0.02) EPS for the quarter, meeting analysts' consensus estimates of ($0.02). The company had revenue of $0.07 million during the quarter, compared to analyst estimates of $0.23 million.

Avivagen Price Performance

Shares of OTCMKTS:VIVXF opened at $0.13 on Friday. The company's 50 day moving average price is $0.14 and its two-hundred day moving average price is $0.15. Avivagen has a 12-month low of $0.12 and a 12-month high of $0.38. The firm has a market cap of $9.33 million, a PE ratio of -1.40 and a beta of 0.13.

About Avivagen

(Get Rating)

Avivagen Inc, a life sciences company, focuses on developing and commercializing products for livestock feeds that support immune function and help animals to achieve their growth and productivity. The company offers OxC-beta Livestock, a premix for inclusion in livestock feeds; Vivamune health chews for dogs; Dr.

See Also

  • Get a free copy of the StockNews.com research report on Avivagen (VIVXF)
  • Could Snap Stock Rebound As Management Restructures?
  • MarketBeat: Week in Review 8/29 – 9/2
  • Hormel Looks Cheap At These Levels
  • Lululemon Set To Soar Into September
  • Could Nike Stock be Oversold, but Still Overvalued?

Receive News & Ratings for Avivagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avivagen and related companies with MarketBeat.com's FREE daily email newsletter.

This presentation is for informational and educational use only and is not a recommendation or endorsement of any particular investment or investment strategy. Investment information provided in this content is general in nature, strictly for illustrative purposes, and may not be appropriate for all investors. It is provided without respect to individual investors’ financial sophistication, financial situation, investment objectives, investing time horizon, or risk tolerance. You should consider the appropriateness of this information having regard to your relevant personal circumstances before making any investment decisions. Past investment performance does not indicate or guarantee future success. Returns will vary, and all investments carry risks, including loss of principal. Moomoo makes no representation or warranty as to its adequacy, completeness, accuracy or timeliness for any particular purpose of the above content.

Moomoo is a financial information and trading app offered by Moomoo Technologies Inc.
In the U.S., investment products and services available through the moomoo app are offered by Moomoo Financial Inc., a broker-dealer registered with the U.S. Securities and Exchange Commission (SEC) and a member of Financial Industry Regulatory Authority (FINRA)/Securities Investor Protection Corporation (SIPC).
In Singapore, investment products and services available through the moomoo app are offered through Moomoo Financial Singapore Pte. Ltd. regulated by the Monetary Authority of Singapore (MAS). Moomoo Financial Singapore Pte. Ltd. is a Capital Markets Services Licence (License No. CMS101000) holder with the Exempt Financial Adviser Status. This advertisement has not been reviewed by the Monetary Authority of Singapore.
In Australia, financial products and services available through the moomoo app are provided by Futu Securities (Australia) Ltd, an Australian Financial Services Licensee (AFSL No. 224663) regulated by the Australian Securities and Investment Commission (ASIC). Please read and understand our Financial Services Guide, Terms and Conditions, Privacy Policy and other disclosure documents which are available on our websites https://www.futuau.com and https://www.moomoo.com/au. Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd. and Futu Securities (Australia) Ltd are affiliated companies.